The pharmacology of ion channels: With particular reference to voltage-gated Ca2+ channels

European Journal of Pharmacology

Volumn 375, Issue 1-3, 1999, Pages 311-325

  Triggle, David J ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

1,4 Dihydropyridine; Ca2+ channel; Ca2+ channel antagonist; Diltiazem; Ion channel; Nifedipine; State dependent interaction; Verapamil

Indexed keywords

1,4 DIHYDROPYRIDINE DERIVATIVE; AMLODIPINE; CALCIUM ANTAGONIST; CALCIUM CHANNEL; DILTIAZEM; FELODIPINE; ION CHANNEL; ISRADIPINE; LACIDIPINE; NICARDIPINE; NIFEDIPINE; NIMODIPINE; NISOLDIPINE; NITRENDIPINE; VERAPAMIL;

ANKLE EDEMA; CONSTIPATION; DRUG MECHANISM; FLUSHING; HEADACHE; HUMAN; ISCHEMIA; NONHUMAN; PRIORITY JOURNAL; RASH; REVIEW; TACHYCARDIA; VERTIGO;

ANIMALS; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS; FORECASTING; HUMANS; ION CHANNEL GATING; ION CHANNELS; MEMBRANE POTENTIALS; MODELS, BIOLOGICAL;

EID: 0033052921     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(99)00329-5     Document Type: Review

References (82)

1. Abascal V.M., Larson M.G., Evans J.C., Blohm A.T., Poli K., Levy D. Calcium antagonists and mortality risk in men and women with hypertension in the Framingham heart study. Arch. Int. Med. 158:1998;1882-1886.
2. Aidley, D.J., Stanfield, P.R., 1956. Ion Channels: Molecules in Action. Cambridge University Press, Cambridge, UK.
3. Armstrong C.M. The vision of the pore. Science. 280:1998;56-58.
4. Armstrong C.M., Hille B. Voltage-gated ion channels and electrical excitability. Neuron. 20:1998;371-380.
5. 2+ channels and in gerbil global cerebral ischemia. Eur. J. Pharmacol. 299:1996;103-112.
6. Bean B.P. Nitrendipine block of cardiac calcium channels: high affinity binding to the inactivated state. Proc. Nat. Acad. Sci. U.S.A. 81:1984;6388-6392.
7. Bean B.P., Cohen C.J., Tsien R.W. Lidocaine block of cardiac sodium channels. J. Gen. Physiol. 81:1983;613-642.
8. Birnbaumer L., Campbell K.P., Catterall W.A., Harpold M.M., Hofmann F., Horne W.A., Mori Y., Scwartz A., Tanabe T., Tsien R.W. The naming of voltage-gated calcium channels. Neuron. 13:1994;505-506.
9. 2+ channels by the NMDA receptor antagonist eliprodil in acutely dissociated rat Purkinje cells. Eur. J. Pharmacol. 294:1995;91-100.
10. Bowersox S.S., Gadbois T., Singh T., Pettus M., Wang X.X., Luther R.R. Selective N-type neuronal voltage-sensitive calcium channel blocker, SNX-111, produces spinal antinociception in rat models of acute, persistent and neuropathic pain. J. Pharmacol. Exp. Therap. 279:1996;1243-1249.
11. Brose W.G., Gutlove D.P., Luther R.R., Bowerson S.S., McGuire D. Use of intrathecal SNX-111, a novel, N-type, voltage-sensitive, calcium channel blocker in the management of intractable brachial plexus avulsion pain. Clin. J. Pain. 13:1997;256-259.
12. 2+ channels by benzothiazepines and phenylalkylamines: class-specific pharmacology and underlying molecular determinants. Mol. Pharmacol. 51:1997;872-881.
13. 1A receptors to N- and L-type calcium channels in C-like rat dorsal root ganglion cells. J. Neurophysiol. 77:1997;3284-3296.
14. Catterall W.A. Function of voltage-gated ion channels. Ann. Rev. Biochem. 64:1995;493-531.
15. Chatterjee, A., Booth, J., Brogley, L., Campbell, G., Cody, W., Geer, J.G., He, J., Hu, L.-Y., Lescosky, L.J., Maolone, T., Miljanich, G., Nadasdi, L., Rafferty, M.J., Sercel, A., Silva, D., Stoehr, S., Song, S., Szoke, B.G., Tarczy-Hornoch, T., Taylor, C., Urge, L., Vartanina, M., 1999. PD 151307 analogs: investigation of tyrosine (OBn) modified derivatives as N-type calcium channel blockers. Abs 118, Medicinal Chemistry Division, 217th National ACS meeting, Los Angeles. March 21-25.
16. 2+ channels in rat and mouse cultured hippocampal pyramidal neurons comparison with N-methyl-D-aspartate receptor antagonist actions. Brit. J. Pharmacol. 113:1997;499-507.
17. Danish Study Group on verapamil in myocardial infarction Effect of verapamil on mortality and major events after acute myocardial infarction. Trial II-Davit II. Am. J. Cardiol. 66:1990;779-785.
18. DEFIANT Research Group Improved diastolic function with the calcium antagonist nisoldipine (core-coat) in patients postmyocardial infarction: results of the DEFIANT study. Eur. Heart. J. 13:1992;1496-1505.
19. De Vry J., Futze J., Post R.M. The management of coexisting depression in patients with dementia: potential of calcium channel antagonists. Clin. Neuropharmacol. 20:1997;22-35.
20. De Waard, M., Gurnett, C.A., Campbell, K.P., 1996. Structural and functional diversity of voltage-activated calcium channels. In: Narahashi, T. (Ed.), Ion Channels, Vol. 4, Plenum Press, New York, NY, pp. 41-87.
21. Docherty R.J., Yeats J.C., Piper A.S. Capsazepine block of voltage-activated calcium channels in adult rat dorsal root ganglion neurons in culture. Brit. J. Pharmacol. 121:1997;1461-1467.
22. + channels. J. Bioenergetics and Biomembranes. 28:1996;231-253.
23. + conduction and selectivity. Science. 280:1998;69-79.
24. Epstein, M. 1998. Safety of calcium antagonists as antihypertensive agents: an update. In: Epstein, M. (Ed.), Calcium Antagonists in Clinical Medicine, 2nd edn., Hanley and Belfus, Philadelphia, PA, pp. 553-571.
25. Ferrante J., Luchowski E., Ruteldege A., Triggle D.J. Binding of 1,4-dihydropyridine calcium channel activator (-) S Bay k 8644 to cardiac preparations. Biochem. Biophys. Res. Comm. 158:1989;149-154.
26. Fleckenstein, A., 1983. Calcium Antagonism in Heart and Smooth Muscle. Experimental Facts and Therapeutic Prospects. Wiley, New York, NY.
27. Furberg C.D., Psaty B.M., Meyer J.V. Dose-related increase in mortality in patients with coronary artery disease. Circulation. 92:1995;1326-1331.
28. 2+ channels by amlodipine. Brit. J. Pharmacol. 122:1997;1136-1140.
29. Godfraind T. Cardioselectivity of calcium antagonists. Cardiovas. Drugs Therap. 8:1994;353-364.
30. Godfraind T., Polster P. Etude comparative de medicaments inhibitant la response contractile de vaissaux isoles d'origine humaine au animale. Therapie. 33:1968;1209-1217.
31. Godfraind T., Salomone S., Dessy C., Verheish B., Dion R., Schoevaerts J.C. Selectivity scale of calcium antagonists in the human cardiovascular system based on in vitro studies. Pharmacol. 20:1992;S34-S41. Suppl. 5.
32. Goldin, S.M., McBurney, R.N., Turner, T.J., 1995. Calcium antagonists for therapy of disorders of the nervous system. In: Peterson, P.L., Phyllis, J.W. (Eds.), Novel Therapies for CNS Injuries: Rationales and Results, CRC Press, Boca Raton, FL, pp. 121-142.
33. Goldstein R., Boccuzzi S., Cruess D., Natel S. Diltiazem increases late-onset congestive heart failure in post-infarction patients with early reduction in rejection fraction. Circulation. 83:1991;52-60.
34. Grantham C.J., Main M.J., Cannell M.B. Fluspirilene block of N-type calcium current in NGF-differentiated PC12 cells. Brit. J. Pharmacol. 111:1994;483-488.
35. Grossman E., Messerli F.H. Effect of calcium antagonists on plasma norepinephrine levels, heart rate and blood pressure. Am. J. Cardiol. 80:1997;1453-1458.
36. Grossman E., Messerli F.H., Grodzicki T., Kowey P. Should a moratorium be placed on sublingual nifedipine capsules given for hypertension save for emergencies and pseudoemergencies? JAMA, J. Am. Med. Assoc. 276:1996;1328-1331.
37. Heilbrunn, L.V., 1943. An Outline of General Physiology, W.B. Saunders, Philadelphia, PA.
38. Helmeste D.M., Tang S.W. The role of calcium in the etiology of the affective disorders. Jap. J. Pharmacol. 77:1998;107-116.
39. Hille B. Local anesthetics: hydrophilic and hydrophobic pathways for the drug-receptor reaction. J. Gen. Physiol. 69:1977;475-496.
40. Hille, B., 1992. Ionic Channels in Excitable Membranes, 2nd edn., Sinauer Associates, Sunderland, MA.
41. Hondeghem L.M., Katzung B.G. Anti-arrhythmic agents: the modulated receptor mechanism for the action of sodium and calcium channel blocking drugs. Ann. Rev. Pharmacol. Toxicol. 24:1985;387-423.
42. Hu H., Marban E. Isoform-specific inhibition of L-type calcium channels by dihydropyridines is independent of isoform-specific gating properties. Mol. Pharmacol. 53:1998;902-907.
43. Hu, L.-Y., Ryder, T.R., Campbell, G.W., Dooley, D.J., Geer, J., Hom, D., Lotarski, S.M., Millerman, E., Rafferty, M.F., Rock, D.M., Song, Y., Stoehr, S.J., Szoke, B.G., Taylor, C.P., Vartanian, M.G., Weber, M.L., 1999. PD 151307 analogs: substituted peptidylamines as novel N-type calcium channel blockers. Abs. 120, Medicinal Chemistry Division, 217th National ACS meeting, Los Angeles, March 21-25.
44. 2+ channel antagonists and activators: comparison of binding characteristics with pharmacology. Drug Dev. Res. 4:1984;254-274.
45. Katz S. Safety of calcium antagonists in patients with congestive heart failure. Clin. Therap. 19:1997;92-113. Suppl. A.
46. Kloner R.A., Vetrovec G.W., Materson B.J., Levenstein M. Safety of long-acting dihydropyridine calcium channel blockers in hypertensive patients. Am. J. Cardiol. 81:1998;163-169.
47. Li S.-N., Brater M., Andreas K. Nimodipine and nitrendipine inhibit N-type Calcium channels in dibutyryl cAMP-differentiated neuroblastoma×glioma hybrid (NG 108-15) cells. Neurosci. Lett. 230:1997;85-88.
48. Li S.-N., Brater M., Andreas K. Nicardipine inhibits N-type calcium channels in dbcAMP-differentiated neuroblastoma×glioma hybrid cells (NG 108-15 cells). Acta Pharmacologica Sinica. 20:1999;117-120.
49. Little H.J. The role of calcium channels on drug dependence. Drug and Alcohol Dependence. 38:1995;173-194.
50. Little W.C., Cheng C.-P., Elvelin L., Nordlander M. Vascular selective Calcium entry blockers in the treatment of cardiovascular disorders: focus on Felodipine. Cardiovas. Drugs Therapy. 9:1995;657-663.
51. Marwick C. Channel blockers clean bill of heath but warns of short-acting nifedipine hazards. JAMA, J. Am. Med. Assoc. 275:1996;423-424.
52. Miljanich G.P., Ramachandran J. Antagonists of neuronal calcium channels: structure, function and therapeutic implications. Ann. Rev. Pharmacol. Toxicol. 35:1995;707-734.
53. Mintz I., Adams M.E., Bean B.P. P-type calcium channels in rat central and peripheral neurons. Neuron. 9:1992;85-95.
54. 2+ channels. J. Bioeng. Biomem. 30:1998;319-334.
55. Multicenter Diltiazem post-infarction trial research group The effects of diltiazem on mortality and reinfarction after myocardial infarction. New Eng. J. Med. 319:1988;385-392.
56. Nelson M.T., Potlack B., Worley J.F., Standen N.B. Calcium channels, potassium channels and voltage-dependence of arterial smooth muscle tone. Am. J. Physiol. 259:1990;C3-C18.
57. Olivera B.M. Conus venom peptides, receptor and ion channel targets, and drug designs. 50 million years of neuropharmacology. Mol. Biol. Cell. 8:1997;2101-2109.
58. Olivera B.M., Miljanich G.P., Ramachandran J., Adams M.E. Calcium channel diversity and neurotransmitter release: the w-conotoxins and w-agatoxins. Ann. Rev. Biochem. 63:1994;823-867.
59. Ortells M.O., Lunt G.G. Evolutionary history of the ligand-gated ion channel super-family of receptors. Trends Neurosci. 18:1995;121-127.
60. Pasty R.M., Heckbert S.R., Koepsell T.D. The risk of myocardial infarction associated with anti-hypertensive drug therapies. JAMA, J. Am. Med. Assoc. 274:1995;620-625.
61. Perez-Viccaino F., Tamargo J., Hof R.P., Ruegg U.T. Vascular selectivity of seven prototype calcium antagonists: a study at the single cell level. J. Cardiovas. Pharmacol. 22:1993;768-775.
62. Pichler M., Wang Z., Grabner-Weiss C., Reimer D., Hering S., Garbner M., Glossmann H., Striessnig J. Block of P/Q-type channels by therapeutic concentrations of aminoglycoside antibiotics. Biochemistry. 35:1996;14659-14664.
63. Rampe, D. (Ed.), 1994. Ion Channels, Drug Dev. Res. 33, 189-372.
64. Rampe D., Triggle D.J. New synthetic ligands for L-type voltage-gated calcium channels. Prog. Drug Res. 40:1993;191-238.
65. Ringer S. A further contribution regarding the influence of the different constituents of the blood on the contraction of the heart. J. Physiol. 4:1883;29-42.
66. Sanguinetti M.C., Kass R.S. Voltage-dependent block of calcium channel current in calf cardiac Purkinje fibers by dihydropyridine calcium channel antagonists. Circ. Res. 55:1984;336-348.
67. Scheuer T. A revised view of local anesthetic action. What channel state is really stabilized? J. Gen. Physiol. 113:1999;3-6.
68. 2+ antagonists in human myocardial tissue. Klin. Wochenschr. 68:1990;797-805.
69. Stefani A., Spadoni F., Bernardi G. Voltage-activated calcium channels. Targets of antiepileptic drug therapy? Epilepsia. 38:1997;959-965.
70. Sun J., Triggle D.J. Calcium channel antagonists: cardiovascular selectivity of action. J. Pharmacol. Exp. Therap. 274:1995;419-426.
71. Triggle, D.J., 1989. Structure-function correlations of 1,4-dihydropyridine calcium channel antagonists and activators, In: Hondeghem, L.M. (Ed.), Molecular and Cellular Mechanisms of Action of Antiarrhythmic Drugs Futura Publishing, Mt. Kiscoe, NY.
72. Uchitel O.D. Toxins affecting calcium channels in neurons. Toxicon. 35:1997;1161-1191.
73. 2+ current by cilnidipine (FRC 8653) in acutely dissociated rat sympathetic neurons. Brit. J. Pharmacol. 122:1997;37-42.
74. 2+ channels: role in channel function. Trends Neurosciences. 24:1998;148-154.
75. Waters D. Proischemic complications of dihydropyridine calcium channel blockers. Circulation. 84:1991;2598-2599.
76. 2+ channel antagonists and activators in cultured neonatal rat ventricular myocytes. Mol. Pharmacol. 35:1989;541-552.
77. Welling A., Kwan Y.W., Bosse E., Flockerzi V., Hofmann F., Kass R.S. Subunit-dependent modulation of recombinant L-type calcium channels. Molecular basis for dihydropyridine tissue selectivity. Circ. Res. 73:1993;974-980.
78. 2+ channels. Circ. Res. 81:1998;526-532.
79. 1 subunit. Neuron. 9:1992;1099-1115.
80. Wibo M. Mode of action of calcium antagonists: voltage-dependence and kinetics of drug-receptor interactions. Pharmacol. Toxicol. 65:1989;1-8.
81. 2+ channels: differences between chicken sympathetic and parasympathetic neurons suggest different regulating mechanisms. Proc. Nat. Acad. Sci. U.S.A. 91:1994;2858-2862.
82. Zheng W., Stoltefuss J., Goldmann S., Triggle D.J. Pharmacologic and radioligand binding studies of 1,4-dihydropyridines in rat cardiac and vascular preparations: stereoselectivity and voltage-dependence of antagonist and activator interactions. Mol. Pharmacol. 41:1992;535-541.